154 related articles for article (PubMed ID: 36656126)
1. Automated Ki-67 labeling index assessment in prostate cancer using artificial intelligence and multiplex fluorescence immunohistochemistry.
Blessin NC; Yang C; Mandelkow T; Raedler JB; Li W; Bady E; Simon R; Vettorazzi E; Lennartz M; Bernreuther C; Fraune C; Jacobsen F; Krech T; Marx A; Lebok P; Minner S; Burandt E; Clauditz TS; Wilczak W; Sauter G; Heinzer H; Haese A; Schlomm T; Graefen M; Steurer S
J Pathol; 2023 May; 260(1):5-16. PubMed ID: 36656126
[TBL] [Abstract][Full Text] [Related]
2. An artificial intelligence algorithm for prostate cancer diagnosis in whole slide images of core needle biopsies: a blinded clinical validation and deployment study.
Pantanowitz L; Quiroga-Garza GM; Bien L; Heled R; Laifenfeld D; Linhart C; Sandbank J; Albrecht Shach A; Shalev V; Vecsler M; Michelow P; Hazelhurst S; Dhir R
Lancet Digit Health; 2020 Aug; 2(8):e407-e416. PubMed ID: 33328045
[TBL] [Abstract][Full Text] [Related]
3. Ki-67 staining is an independent correlate of biochemical failure in prostate cancer treated with radiotherapy.
Cowen D; Troncoso P; Khoo VS; Zagars GK; von Eschenbach AC; Meistrich ML; Pollack A
Clin Cancer Res; 2002 May; 8(5):1148-54. PubMed ID: 12006531
[TBL] [Abstract][Full Text] [Related]
4. Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer.
Zellweger T; Günther S; Zlobec I; Savic S; Sauter G; Moch H; Mattarelli G; Eichenberger T; Curschellas E; Rüfenacht H; Bachmann A; Gasser TC; Mihatsch MJ; Bubendorf L
Int J Cancer; 2009 May; 124(9):2116-23. PubMed ID: 19117060
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of proliferation activity and neuroendocrine differentiation to predict treatment failure after radical prostatectomy.
May M; Siegsmund M; Hammermann F; Loy V; Gunia S
Scand J Urol Nephrol; 2007; 41(5):375-81. PubMed ID: 17853019
[TBL] [Abstract][Full Text] [Related]
6. Biopsy tissue microarray study of Ki-67 expression in untreated, localized prostate cancer managed by active surveillance.
Jhavar S; Bartlett J; Kovacs G; Corbishley C; Dearnaley D; Eeles R; Khoo V; Huddart R; Horwich A; Thompson A; Norman A; Brewer D; Cooper CS; Parker C
Prostate Cancer Prostatic Dis; 2009; 12(2):143-7. PubMed ID: 18762814
[TBL] [Abstract][Full Text] [Related]
7. Independent real-world application of a clinical-grade automated prostate cancer detection system.
da Silva LM; Pereira EM; Salles PG; Godrich R; Ceballos R; Kunz JD; Casson A; Viret J; Chandarlapaty S; Ferreira CG; Ferrari B; Rothrock B; Raciti P; Reuter V; Dogdas B; DeMuth G; Sue J; Kanan C; Grady L; Fuchs TJ; Reis-Filho JS
J Pathol; 2021 Jun; 254(2):147-158. PubMed ID: 33904171
[TBL] [Abstract][Full Text] [Related]
8. High Inter- and Intratumoral Variability of Ki67 Labeling Index in Newly Diagnosed Prostate Cancer with High Gleason Scores.
Vlajnic T; Brunner P; Eppenberger-Castori S; Rentsch CA; Zellweger T; Bubendorf L
Pathobiology; 2022; 89(2):74-80. PubMed ID: 34555829
[TBL] [Abstract][Full Text] [Related]
9. Focal neuroendocrine differentiation lacks prognostic significance in prostate core needle biopsies.
Casella R; Bubendorf L; Sauter G; Moch H; Mihatsch MJ; Gasser TC
J Urol; 1998 Aug; 160(2):406-10. PubMed ID: 9679888
[TBL] [Abstract][Full Text] [Related]
10. Relationship of Ki-67 labeling index to DNA-ploidy, S-phase fraction, and outcome in prostate cancer treated with radiotherapy.
Khoo VS; Pollack A; Cowen D; Joon DL; Patel N; Terry NH; Zagars GK; von Eschenbach AC; Meistrich ML; Troncoso P
Prostate; 1999 Nov; 41(3):166-72. PubMed ID: 10517874
[TBL] [Abstract][Full Text] [Related]
11. Tissue microarray analysis reveals prognostic significance of syndecan-1 expression in prostate cancer.
Zellweger T; Ninck C; Mirlacher M; Annefeld M; Glass AG; Gasser TC; Mihatsch MJ; Gelmann EP; Bubendorf L
Prostate; 2003 Apr; 55(1):20-9. PubMed ID: 12640657
[TBL] [Abstract][Full Text] [Related]
12. Automated Prognosis Marker Assessment in Breast Cancers Using BLEACH&STAIN Multiplexed Immunohistochemistry.
Mandelkow T; Bady E; Lurati MCJ; Raedler JB; Müller JH; Huang Z; Vettorazzi E; Lennartz M; Clauditz TS; Lebok P; Steinhilper L; Woelber L; Sauter G; Berkes E; Bühler S; Paluchowski P; Heilenkötter U; Müller V; Schmalfeldt B; von der Assen A; Jacobsen F; Krech T; Krech RH; Simon R; Bernreuther C; Steurer S; Burandt E; Blessin NC
Biomedicines; 2023 Nov; 11(12):. PubMed ID: 38137396
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of Ki-67 for prostate cancer death in a conservatively managed cohort.
Fisher G; Yang ZH; Kudahetti S; Møller H; Scardino P; Cuzick J; Berney DM;
Br J Cancer; 2013 Feb; 108(2):271-7. PubMed ID: 23329234
[TBL] [Abstract][Full Text] [Related]
14. Ki-67 is an independent predictor of prostate cancer death in routine needle biopsy samples: proving utility for routine assessments.
Kammerer-Jacquet SF; Ahmad A; Møller H; Sandu H; Scardino P; Soosay G; Beltran L; Cuzick J; Berney DM
Mod Pathol; 2019 Sep; 32(9):1303-1309. PubMed ID: 30976102
[TBL] [Abstract][Full Text] [Related]
15. Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic study.
Ström P; Kartasalo K; Olsson H; Solorzano L; Delahunt B; Berney DM; Bostwick DG; Evans AJ; Grignon DJ; Humphrey PA; Iczkowski KA; Kench JG; Kristiansen G; van der Kwast TH; Leite KRM; McKenney JK; Oxley J; Pan CC; Samaratunga H; Srigley JR; Takahashi H; Tsuzuki T; Varma M; Zhou M; Lindberg J; Lindskog C; Ruusuvuori P; Wählby C; Grönberg H; Rantalainen M; Egevad L; Eklund M
Lancet Oncol; 2020 Feb; 21(2):222-232. PubMed ID: 31926806
[TBL] [Abstract][Full Text] [Related]
16. Molecular markers of outcome after radiotherapy in patients with prostate carcinoma: Ki-67, bcl-2, bax, and bcl-x.
Pollack A; Cowen D; Troncoso P; Zagars GK; von Eschenbach AC; Meistrich ML; McDonnell T
Cancer; 2003 Apr; 97(7):1630-8. PubMed ID: 12655519
[TBL] [Abstract][Full Text] [Related]
17. Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study.
Berney DM; Gopalan A; Kudahetti S; Fisher G; Ambroisine L; Foster CS; Reuter V; Eastham J; Moller H; Kattan MW; Gerald W; Cooper C; Scardino P; Cuzick J
Br J Cancer; 2009 Mar; 100(6):888-93. PubMed ID: 19293807
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of phospho-histone H3 in prostate carcinoma.
Nowak M; Svensson MA; Carlsson J; Vogel W; Kebschull M; Wernert N; Kristiansen G; Andrén O; Braun M; Perner S
World J Urol; 2014 Jun; 32(3):703-7. PubMed ID: 23887713
[TBL] [Abstract][Full Text] [Related]
19. Ki67 labeling index in core needle biopsies independently predicts tumor-specific survival in prostate cancer.
Bubendorf L; Tapia C; Gasser TC; Casella R; Grunder B; Moch H; Mihatsch MJ; Sauter G
Hum Pathol; 1998 Sep; 29(9):949-54. PubMed ID: 9744310
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of Ki-67, p53, and Bcl-2 expression in prostate cancer patients with lymph node metastases: a retrospective immunohistochemical analysis.
Masuda M; Takano Y; Iki M; Asakura T; Hashiba T; Noguchi S; Hosaka M
Pathol Int; 1998 Jan; 48(1):41-6. PubMed ID: 9589463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
